Faeth Therapeutics, Inc. FTH
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Faeth Therapeutics, Inc. (FTH) is a healthcare company listed in the US with a market value of about $259M.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -58%.
About Faeth Therapeutics
Faeth Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count fell by 18% over three years (buybacks).
Score: 0.6 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$21M | -$30M | -$34M | -$49M | -$37M | -$20M |
| Free cash flow | -$20M | -$25M | -$32M | -$39M | -$32M | -$19M |
| EPS (diluted) | $-0.84 | $-1.20 | $-1.22 | $-1.58 | $-1.33 | $-12.53 |
| Net margin | — | — | — | — | — | — |
| ROIC | -111.3% | -78.8% | -42.1% | -36.4% | -20.2% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 13 analysts is $56.15, 460% above the current price; targets range from $40.00 to $69.00; the consensus rating is “Strong buy”; expected EPS is $-15.60 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Faeth Therapeutics pay a dividend?
Not currently.
Is Faeth Therapeutics a good stock to buy?
We do not give buy or sell advice. Faeth Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.